TELIK, INC.
Patent Owner
Stats
- 25 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- Nov 06, 2014 most recent publication
Details
- 25 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 891 Total Citation Count
- Oct 11, 1988 Earliest Filing
- 63 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
8841476 Preparation of crystalline ezatiostat hydrochloride ansolvate form DApr 26, 11Sep 23, 14[A61K, C07C, C07K]
8759303 Compositions and methods for treating myelodysplastic syndromeMay 16, 11Jun 24, 14[A61K, A01N]
6506739 Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agentsMay 01, 01Jan 14, 03[A61K, C07F, A61P]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2014/0329,754 COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROMEAbandonedApr 29, 14Nov 06, 14[A61K]
8410163 Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitorsExpiredFeb 09, 10Apr 02, 13[A61K, C07D]
2013/0035,389 METHODS FOR TREATING MYELODYSPLASTIC SYNDROME WITH EZATIOSTATAbandonedApr 02, 12Feb 07, 13[A61K, A61P, C40B]
2012/0288,554 CANFOSFAMIDE MONOTHERAPY FOR TREATING MULTIPLE MYELOMAAbandonedMay 12, 11Nov 15, 12[A61K, C07F, A61P]
2012/0165,260 CRYSTALLINE EZATIOSTAT HYDROCHLORIDE ANSOLVATEAbandonedMar 04, 11Jun 28, 12[A61K, A61P, C07K]
8207121 Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compoundExpiredOct 15, 07Jun 26, 12[C12N, G01N, A61P]
8198247 Process for and intermediates in the preparation of canfosfamide and its saltsExpiredDec 21, 04Jun 12, 12[A61K]
8129396 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitorsExpiredSep 25, 09Mar 06, 12[C07D]
2011/0301,102 COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROMEAbandonedMay 16, 11Dec 08, 11[A61K, A61P]
2011/0301,199 COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROMEAbandonedMay 16, 11Dec 08, 11[A61K, A61P]
7872134 2-{[2-(substituted amino)ethyl]sulfonyl}ethyl N,N-bis(2-chloroethyl)phosphorodiamidatesExpiredDec 12, 07Jan 18, 11[A61K, C07F]
7655799 2{[2-(substituted amino)ethyl]sulfonyl}ethyl N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidatesExpiredNov 29, 06Feb 02, 10[A61K, C07F]
2008/0159,980 Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapyAbandonedOct 15, 07Jul 03, 08[A61K, A61P]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.